HomeCompareNPNKF vs ARCC

NPNKF vs ARCC: Dividend Comparison 2026

NPNKF yields 2.21% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NPNKF wins by $81.3K in total portfolio value· pulled ahead in Year 3
10 years
NPNKF
NPNKF
● Live price
2.21%
Share price
$32.75
Annual div
$0.73
5Y div CAGR
47.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$105.8K
Annual income
$37,802.15
Full NPNKF calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — NPNKF vs ARCC

📍 NPNKF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNPNKFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NPNKF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NPNKF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NPNKF
Annual income on $10K today (after 15% tax)
$188.24/yr
After 10yr DRIP, annual income (after tax)
$32,131.83/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, NPNKF beats the other by $32,130.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NPNKF + ARCC for your $10,000?

NPNKF: 50%ARCC: 50%
100% ARCC50/50100% NPNKF
Portfolio after 10yr
$65.1K
Annual income
$18,901.65/yr
Blended yield
29.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

NPNKF
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
7.1
Piotroski
4/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NPNKF buys
0
ARCC buys
0
No recent congressional trades found for NPNKF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNPNKFARCC
Forward yield2.21%10.65%
Annual dividend / share$0.73$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR47.7%-50%
Portfolio after 10y$105.8K$24.5K
Annual income after 10y$37,802.15$1.14
Total dividends collected$78.8K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy

Year-by-year: NPNKF vs ARCC ($10,000, DRIP)

YearNPNKF PortfolioNPNKF Income/yrARCC PortfolioARCC Income/yrGap
1$11,027$327.10$11,373$532.74$346.00ARCC
2$12,297$497.89$12,608$279.46$311.00ARCC
3← crossover$13,924$766.41$13,809$142.90+$115.00NPNKF
4$16,097$1,197.93$15,042$72.20+$1.1KNPNKF
5$19,135$1,911.61$16,341$36.27+$2.8KNPNKF
6$23,611$3,136.81$17,732$18.18+$5.9KNPNKF
7$30,607$5,342.88$19,231$9.10+$11.4KNPNKF
8$42,310$9,560.33$20,851$4.55+$21.5KNPNKF
9$63,514$18,242.73$22,605$2.28+$40.9KNPNKF
10$105,762$37,802.15$24,504$1.14+$81.3KNPNKF

NPNKF vs ARCC: Complete Analysis 2026

NPNKFStock

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

Full NPNKF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this NPNKF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NPNKF vs SCHDNPNKF vs JEPINPNKF vs ONPNKF vs KONPNKF vs MAINNPNKF vs HTGCNPNKF vs GBDCNPNKF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.